Novo Nordisk’s stock popped Monday after it announced a cash discount for uninsured Ozempic users and gained FDA approval for Wegovy to be used for liver treatment. The pharma giant's stock rose more ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

People who are prescribed Ozempic to treat type 2 diabetes, but whose insurance does not cover it, or who don’t have ...

Researchers urged caution, recommending that diabetic patients on GLP-1 therapies undergo regular eye screening….

Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated ...

Six in ten Brits (61 per cent) believe the correct modern etiquette is to call ahead of a dinner or lunch party - to notify ...

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.

Dow Jones Top Company Headlines at 11 AM ET: Air Canada Halts Guidance as Flight Attendant Strike Continues | Soho ... Air Canada withdrew its financial targets for the year as a strike by flight ...

The FDA has approved Novo Nordisk’s Wegovy to treat metabolic associated steatohepatitis, or MASH, in adults who have excessive scar tissue in the liver. MASH is a serious liver condition linked to ...

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its ...